LA BioMed closes $50M bond sale to finance biotech research lab

LA BioMed is planning to open a new $63 milion, four-story bioscience research and incubator in February 2019. (Getty/choness)

LA BioMed—a nonprofit research organization located on the campus of Harbor-UCLA Medical Center campus—closed a $50 million bond sale to benefit a new biomedical research building and biotech incubator.

The sale of the Series 2018 Tax-Exempt Revenue Bonds, issued by the California Health Facilities Financing Authority, was led by Wells Fargo Securities. 

“The proceeds will help us create new innovative biomedical solutions with a new research building, biotech incubator and a campus that facilitates the bed-to-bench-to bed cycle of innovation we have nurtured at LA BioMed," said Dr. David Meyer, president and CEO of LA BioMed.

Free Webinar

Take Control of Your Escalating Claim Costs through a Comprehensive Pre-payment Hospital Bill Review Solution

Today managing high dollar claim spend is more important than ever for Health Plans, TPAs, Employers, and Reinsurers, and can pose significant financial risks. How can these costs be managed without being a constant financial drain on your company resources? Our combination of the right people and the right technology provides an approach that ensures claims are paid right, the first time. Register Now!

RELATED: High ICU use increases costs, number of invasive procedures

LA BioMed is planning to open a new $63 million, four-story bioscience research and incubator in February 2019. It will be focused on improving healthcare through the research and development of new treatments and therapies and will offer space to incubate between 25 and 30 companies, officials said.

LA BioMed has launched 13 spin-offs since it launched in 2006. It is affiliated with the David Geffen School of Medicine at UCLA.

RELATEDHow some major health systems are overcoming the barriers to launching precision medicine programs

While academic health centers have always invested in tech transfer activities, they have increasingly poured investments into upgrading their biomedical research and their incubation spaces for commercialization in recent years. In July, RWJBarnabas Health announced a $1 billion partnership with Rutgers University as part of a bigger public-private partnership to create a jointly operated academic health system, including the construction of a new clinical and research building for the Rutgers Cancer Institute of New Jersey.

In April, Nashville-based Vanderbuilt University Medical Canter announced it would launch a subsidiary that will help commercialize its researchers' work with outside drug companies and Falls Church, Virginia-based Inova Health System, which is creating a personalized health campus, started both an accelerator and a drug discovery program as part of a vision to enhance research partnerships and creating new revenue streams.

Suggested Articles

Despite efforts to improve patient safety over the past 20 years, results have not been optimal. We raise vital questions and renewed areas of focus.

Learn how health plans can demonstrate agility with analytics to shape benefit plans in a time of healthcare transformation.

Providers complain a controversial model that ties certain drug prices to those paid overseas could cause a major financial hit.